{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:02:25Z","timestamp":1722888145935},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1987,1,1]],"date-time":"1987-01-01T00:00:00Z","timestamp":536457600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1987]]},"DOI":"10.1007\/bf00570491","type":"journal-article","created":{"date-parts":[[2004,11,22]],"date-time":"2004-11-22T15:20:25Z","timestamp":1101136825000},"page":"230-234","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of acute leukemia and malignant lymphoma with (2?R)-4?-O-tetrahydropyranyladriamycin"],"prefix":"10.1007","volume":"20","author":[{"given":"Ryuzo","family":"Ohno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoji","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichita","family":"Amaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Konno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Majima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Masaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harumitsu","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Oguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatuo","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumimaro","family":"Takaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Wakui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the THP Study Group on Hematological Malignancy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"247","volume":"6","author":"RH Blum","year":"1975","unstructured":"Blum RH (1975) An overview of studies with adriamycin (NSC-123127) in the United States. Cancer Chemothr Rep 6: 247?251","journal-title":"Cancer Chemothr Rep"},{"key":"CR2","first-page":"149","volume":"80","author":"RH Blum","year":"1974","unstructured":"Blum RH, Carter SK (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80: 149?259","journal-title":"Ann Intern Med"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0140-6736(69)91296-3","volume":"I","author":"M Boiron","year":"1969","unstructured":"Boiron M, Jacquillat C, Weil M, Tanzer J, Levy D, Sultan C, Bernard J (1969) Daunorubicin in the treatment of acute myelocytic leukaemia. Lancet I: 330?333","journal-title":"Lancet"},{"key":"CR4","first-page":"2572","volume":"30","author":"G Bonadonna","year":"1970","unstructured":"Bonadonna G, Monfardini S, Lena MD, Fossa-Bellani F, Beretta G (1970) Phase I and preliminary phase II evaluation of adriamycin (NCS-123127) Cancer Res 30: 2572?2582","journal-title":"Cancer Res"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/jama.1969.03150200067005","volume":"207","author":"RS Bornstein","year":"1969","unstructured":"Bornstein RS, Theologides A, Kennedy BJ (1969) Daunorubicin in acute myelogenous leukemia in adults. J Am Med Assoc 207: 1301?1306","journal-title":"J Am Med Assoc"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/jnci\/55.6.1265","volume":"55","author":"SK Carter","year":"1975","unstructured":"Carter SK (1975) Adriamycin ? a review. J Natl Cancer Inst 55: 1265?1274","journal-title":"J Natl Cancer Inst"},{"key":"CR7","first-page":"5","volume":"4","author":"SK Carter","year":"1980","unstructured":"Carter SK (1980) The clinical evaluation of analogs: III. Anthracyclines. Cancer Chemother Pharmacol 4: 5?10","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR8","first-page":"375","volume":"6","author":"CA Coltman","year":"1975","unstructured":"Coltman CA (1975) Adriamycin (NCS-123127) in the treatment of lymphomas: Southwest Oncology Group Studies. Cancer Chemother Rep 6: 375?380","journal-title":"Cancer Chemother Rep"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.7164\/antibiotics.32.1085","volume":"32","author":"D Dantchev","year":"1979","unstructured":"Dantchev D, Paintrand M, Hayat M, Bourut C, Math\u00e9 G (1979) Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP) as observed by electron and light microscopy. J Antibiot (Tokyo) 32: 1085?1086","journal-title":"J Antibiot (Tokyo)"},{"key":"CR10","first-page":"84","volume":"31","author":"B Jones","year":"1971","unstructured":"Jones B, Holland JK, Morrison AR, Lee SL, Sinks LF, Cuttner J, Rausen A, Kung F, Pluss HJ, Haurani FI, Patterson RB, Blom J, Burgert EM Jr, Moon JH, Chevalier L, Sawitsky A, Albala MM, Forcier RJ, Falkson GF, Glidewell O (1971) Daunorubicin (NSC 82151) in the treatment of advanced childhood lymphoblastic leukemia. Cancer Res 31: 84?90","journal-title":"Cancer Res"},{"key":"CR11","first-page":"368","volume":"13","author":"K Kimura","year":"1986","unstructured":"Kimura K (1986) A phase II study of (2?R)-4?-o-tetrahydropyranyladriamycin (THP) in patients with hematological malignancies. Gan-to-Kagakuryoho 13: 368?375","journal-title":"Gan-to-Kagakuryoho"},{"key":"CR12","first-page":"1220","volume":"7","author":"K Kitajima","year":"1980","unstructured":"Kitajima K, Takashashi I, Yorimitsu S, Koi B, Tokioka M, Lai M, Masaki K, Sakano M, Hara M, Adachi T, Kawakubo K, Kimura I, Sanada H (1980) Treatment of refractory adult leukemia with aclacinomycin-A ? phase II study. Gan-to-Kagakuryoho 7: 1220?1227","journal-title":"Gan-to-Kagakuryoho"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7164\/antibiotics.36.312","volume":"36","author":"S Kunitomo","year":"1983","unstructured":"Kunitomo S, Miura K, Takahashi Y, Takeuchi T, Umezawa H (1983) Rapid uptake by cultured tumor cells and intracellular behavior of 4?-o-tetrahydropyranyladriamycin. J Antibiot (Tokyo) 36: 312?317","journal-title":"J Antibiot (Tokyo)"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.7164\/antibiotics.37.1697","volume":"37","author":"S Kunimoto","year":"1984","unstructured":"Kunimoto S, Miura K, Umezawa K, Xu C-Z, Masuda T, Takeuchi T, Umezawa H (1984) Cellular uptake and effulux and cytostatic activity of 4?-o-tetrahydropyranyladriamycin in adriamycin-sensitive and-resistant tumor cell lines. J Antibiot (Tokyo) 37: 1697?1702","journal-title":"J Antibiot (Tokyo)"},{"key":"CR15","first-page":"134","volume":"10","author":"H Majima","year":"1983","unstructured":"Majima H (1983) Exploratory clinical study of 4?-o-tetrahydropyranyl doxorubicin (THP) ? phase I. Gan-to-Kagakuryoho 10: 134?140","journal-title":"Gan-to-Kagakuryoho"},{"key":"CR16","first-page":"542","volume":"13","author":"H Majima","year":"1986","unstructured":"Majima H, Iguchi H, Tone H (1986) Pharmacokinetic studies of THP (tetrahydropyranyladriamycin). Gan-to-Kagakuryoho 13: 542?548","journal-title":"Gan-to-Kagakuryoho"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/bmj.3.5612.227","volume":"III","author":"JS Malpas","year":"1968","unstructured":"Malpas JS, Scott RB (1968) Rubidomycin in acute leukaemia in adults. Br Med J III: 227?229","journal-title":"Br Med J"},{"key":"CR18","first-page":"259","volume":"1","author":"G Math\u00e9","year":"1978","unstructured":"Math\u00e9 G, Bayssas M, Guouvenia J, Dantchev D, Ribaud P, Machover D, Misset JL, Schwarzenberg L, Jasmin C, Hayat M (1978) Preliminary results of a phase II trial of aclacinomycin in acute leukemia and lymphosarcoma. Cancer Chemother Pharmacol 1: 259?262","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogdtraten B, Staquet M, Winkle A (1981) Reporting results of cancer treatment. Cancer 47: 207?215","journal-title":"Cancer"},{"key":"CR20","first-page":"261","volume":"13","author":"O Nakajima","year":"1986","unstructured":"Nakajima O, Imamura Y, Matsumoto A, Koyama Y, Shomura T, Kawamura K, Murata S (1986) Comparative studies on pharmacokinetics between THP and adriamycin in the same patients. Gan-to-Gagakuryoho 13: 261?270","journal-title":"Gan-to-Gagakuryoho"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00172076","volume":"1","author":"M Ogawa","year":"1983","unstructured":"Ogawa M, Miyamoto H, Inagaki J, Horikoshi N, Ezaki K, Inoue K, Ikeda N, Usui N, Nakada H (1983) Phase I clinical trial of a new anthracycline, 4?-o-tetrahydro-pyranyladriamycin. Invest New Drugs 1: 169?172","journal-title":"Invest New Drugs"},{"key":"CR22","first-page":"1060","volume":"13","author":"T Saito","year":"1986","unstructured":"Saito T, Kasai Y, Wakui A, Furue H, Majima H, Niitani H, Niijima T, Takeda C, Abe O, Kimura K, Ohta K, Yamada K, Taguchi T, Kimura J, Hattori T, Inokuchi K, Kato T (1986) Phase II study of (2?R)-4?-o-tetrahydropyranyladriamycin (THP) in patients with solid tumors. Gan-to-Kagakuryoho 13: 1060?1069","journal-title":"Gan-to-Kagakuryoho"},{"key":"CR23","first-page":"111","volume":"10","author":"H Suzuki","year":"1980","unstructured":"Suzuki H, Kawashima K, Yamada K, Minami S, Kato Y, Tanimoto M, Yamada H, Isobe K, Hayashi K, Yamaguchi H, Takamatsu J, Watanabe E, Kodera Y, Shiku H, Kamiya T, Ohno R, Morishita H, Yokomaku S, Yoshida K, Ogura M (1980) Phase I and preliminary phase II studies on aclacinomycin A in patients with acute leukemia. Jpn J Clin Oncol 10: 111?118","journal-title":"Jpn J Clin Oncol"},{"key":"CR24","first-page":"1361","volume":"7","author":"T Takubo","year":"1980","unstructured":"Takubo T, Sonoda T, Namiuchi S, Ueda T, Shibata H, Nakamura H, Masaoka T, Yoshitake J (1980) Clinical results of aclacinomycin A in hematopoietic malignancies. Gan-to-Kagakuryoho 7: 1361?1365","journal-title":"Gan-to-Kagakuryoho"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K","volume":"20","author":"C Tan","year":"1967","unstructured":"Tan C, Tasaka H, Yu K-P, Murphy ML, Karnofsky DA (1967) Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 20: 333?353","journal-title":"Cancer"},{"key":"CR26","first-page":"1462","volume":"42","author":"T Tsuruo","year":"1982","unstructured":"Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) 4?-o-Tetrahydropyranyladriamycin as a potential new antitumor agent. Cancer Res 42: 1462?1467","journal-title":"Cancer Res"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.7164\/antibiotics.32.1082","volume":"32","author":"H Umezawa","year":"1979","unstructured":"Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, Tatsuta K, Takeuchi T (1979) Tetrahydropyrany derivatives of daunomycin and adriamycin. J Antibiot (Tokyo) 32: 1082?1084","journal-title":"J Antibiot (Tokyo)"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1620\/tjem.146.1","volume":"146","author":"Y Uzuka","year":"1985","unstructured":"Uzuka Y, Saito Y (1985) THP in the treatment of acute promyelocytic leukemia. Tohoku J Exp Med 146: 1?8","journal-title":"Tohoku J Exp Med"},{"key":"CR29","first-page":"118","volume":"12","author":"A Wakui","year":"1985","unstructured":"Wakui A, Yokoyama M, Konno K, Nakai Y, Sakano T, Koyama Y, Imamura Y, Nakajima O, Niijima T, Akaza H, Kimura I, Ohnoshi T, Hiraki S, Kato T, Nishimura H, Umezu J, Saito T (1985) Phase I trial of 4?-o-tetrahydropyranyldoxorubicin (THP) ? multi-institutional cooperative study. Gan-to-Kagakuryoho 12: 118?124","journal-title":"Gan-to-Kagakuryoho"},{"key":"CR30","first-page":"369","volume":"6","author":"PH Wiernik","year":"1975","unstructured":"Wiernik PH (1975) Use of adriamycin (NSC 123127) in hematologic malignancies. Cancer Chemother Rep 6: 369?373","journal-title":"Cancer Chemother Rep"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00570491.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00570491\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00570491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T19:03:39Z","timestamp":1554836619000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00570491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1987]]}},"alternative-id":["BF00570491"],"URL":"https:\/\/doi.org\/10.1007\/bf00570491","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[1987]]}}}